Percutaneous left atrial appendage transcatheter occlusion for patients with atrial fibrillation unable to take warfarin.
Anticoagulation with warfarin for atrial fibrillation is frequently difficult. A transcatheter method to exclude the left atrial appendage from the circulation could be an advantage for selected patients. Percutaneous left atrial appendage transcatheter occlusion is a catheter-based delivery of an occlusive nitinol cage to the neck of the left atrial appendage. The device obliterates the left atrial appendage, eliminating a major source of thromboembolism. Animal studies have confirmed device coverage with an endocardial layer within 6 months and distal atrial appendage fibrosis. A standard transseptal approach from the right femoral vein is used. Patients leave the hospital within 1 day. Six-month follow-up of European and US safety and efficacy trials has shown favorable outcomes in minimizing thromboembolic events and few complications related to placement or healing of the device. Further clinical studies will be needed to establish which patients will be best treated with this device.